Form 4: Quest Diagnostics Counsel Sells Shares in Routine Transactions

Quest Diagnostics' SVP & General Counsel, Michael E. Prevoznik, reported routine sales of common stock, including tax-related dispositions and sales under a 10b5-1 plan.

Summary

• Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics Inc. (DGX), reported two dispositions of common stock.
• On March 2, 2026, 288 shares of common stock were sold at a price of $204.86 per share to satisfy tax obligations arising from the vesting of restricted share units.
• On March 3, 2026, an additional 526 shares of common stock were sold at a price of $207.73 per share, executed pursuant to a pre-arranged Rule 10b5-1 sales plan.
• Following these transactions, Mr. Prevoznik directly beneficially owns 37,557 shares of common stock.
• Additionally, Mr. Prevoznik indirectly holds 5,737 shares through the Company's 401(k) and/or Supplemental Deferred Compensation Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The reported transactions are routine insider sales for tax purposes and under a pre-arranged plan, which do not typically indicate a change in management's confidence or company fundamentals.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those related to tax obligations or pre-arranged 10b5-1 plans, are common across all industries and typically do not signal significant shifts in company or industry outlook. These transactions are part of standard executive compensation and financial planning.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by an executive for routine purposes is unlikely to have a material impact on the company's stock price or long-term shareholder value.

Key Dates

Recommendation

The reported insider transactions are routine and pre-planned, involving a relatively small number of shares for tax obligations and a 10b5-1 plan. These transactions do not provide new material information that would warrant a change in investment recommendation for Quest Diagnostics. Investors should continue to hold based on broader company fundamentals and market conditions, not these specific insider sales.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Executive Compensation, Tax Obligations